2nd Quarter 2026 Results

2nd Quarter 2026 Sales


$25.3B Worldwide increased ▲ **6.6%**

Excluding the impact of translational currency
Stelara impacted results by ~(460) basis points
Worldwide increased ▲ **5.6%**[1]

Diluted earnings per share (EPS) **$2.27**

Adjusted diluted earnings per share[1]
$2.90 Worldwide increased ▲ **4.7%**





Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

"Johnson & Johnson delivered strong second-quarter results, demonstrating the power of our innovation, the depth of our portfolio and the momentum in our pipeline as we advance transformative treatments that address the world's toughest health challenges. With raised guidance and quarterly sales surpassing $25 billion, we are on track to meet our 2026 target of more than $100 billion in annual revenue for the first time in our Company's 140-year history."

$16.4 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 7.8% or 6.8% operationally[2]. Stelara impacted results[2] by ~(760) basis points. Primary operational drivers:

Tremfya® (guselkumab)
DARZALEX® (daratumumab)
CARVYKTI® (ciltacabtagene autoleucel)
Spravato™ (esketamine) CII nasal spray
CAPLYTA® (lumateperone) capsules 42 mg
RYBREVANT® (amivantamab-vmjw) + LAZCLUZE™ (lazertinib)
TECVAYLI® (teclistamab-cqyv)
Erleada® (apalutamide)

$8.9 billion Worldwide MedTech sales

MedTech worldwide reported sales increased 4.5% or 3.6% operationally[2]. Primary operational drivers:

- Contact Lenses
- Trauma
- Wound Closure & Healing
- Electrophysiology
- Shockwave
- Biosurgery

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on July 15, 2026 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx
[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
[2] Non-GAAP measure; excludes the impact of translational currency.
Note: Values may be rounded

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on July 15, 2026 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson&Johnson